Navigation Links
ECNP expresses concern at AstraZeneca neuroscience pull-out
Date:2/6/2012

The European College of Neuropsychopharmacology expresses its deep concern at the recently announced withdrawal by AstraZeneca from neuroscience drug research. AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Disorders of the brain are Europe's pre-eminent health care concern of the future," says ECNP president, Joseph Zohar, professor of psychiatry at Tel Aviv University. "Medications, properly targeted, are in almost all cases the key to effective treatment. To have a major player like AstraZeneca, with an outstanding history of innovation and development in disorders of the brain, pull out of the field in this way will inevitably affect Europeans' access to high-quality medications in the future. This is not good news for patients."

Research sponsored by ECNP shows that more than a third of all Europeans experience some form of mental disorder in any given year, at a total cost to the region of some 800 billion per annum. The direct medical costs of these disorders constitute almost a quarter of the European Union's total health care expenditure, with indirect costs from work absences to enforced early retirement almost twice as much again. The social and emotional costs are incalculable.

AstraZeneca's pull-out is especially disturbing given that it follows a series of similar withdrawals in the last two years by major pharmaceutical companies, including GlaxoSmithKline, Pfizer, Merck, Sanofi and Novartis, who have all significantly downsized their neuroscience commitment. There is a growing sense that neuroscience in Europe is now facing a severe crisis.

"Neuroscience has long been one of Europe's outstanding scientific strengths," says ECNP secretary, Sven Ove gren, professor of neuroscience at Sweden's Karolinska Institutet. "The loss of hundreds of research positions in the field is an enormous blow. Coming on top of similar closures at almost all of Europe's big pharma companies, it's a very worrying development. What's now urgently needed is united action from all those interested in Europe's neuroscientific future to ensure that the region's neuroscience research base of which pharma is an indispensible part does not suffer permanent and possibly irreversible damage."


'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-55734
European College of Neuropsychopharmacology
Source:Eurekalert

Related medicine news :

1. Supportive of intent of ACO proposed rule, ACP expresses concern
2. IHRSA Expresses Its Ardent Support of America's First-Ever National Physical Activity Plan and Accepts Role as Co-Chair of Implementation Sub-Committee
3. U.S. African Chamber of Commerce President Expresses Concern over Health Care Bill
4. Cases of Tamiflu-Resistant Flu Concern Experts
5. Women should still be concerned about hormone replacement therapy, say McMaster researchers
6. Buildup of Newer Flame Retardants Concerns Scientists
7. Potential concern about drugs in clinical trial
8. Group sex among adolescents a public health concern, new study says
9. 15 new conservation concerns
10. Concerns about teen sexting overblown, according to new UNH research
11. Internists address dual concerns of privacy and protection of health data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... , ... Valentine’s Day is nearly upon us, and most singles could probably ... flawless hair, and a sparkling personality are all well and good, but if somebody ... home with Rover. (Actually, man’s best friend might not even want to be near ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly ... vein visualization technology should be used to ensure patient safety when placing an ... INS Standards mandate the use of vein visualization technology in patients with difficult ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
Breaking Medicine Technology: